The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren’s Syndrome

Table 1

Clinical and laboratory characteristics in patients with pSS and healthy controls.

Characteristics	pSS	HCs	p value
Age	57.84 ± 13.01	51.59 ± 18.58	0.158
Sex (female : male)	56 : 2	15 : 1	0.524
Disease duration (years)	7.53 ± 6.95	NA
Xerophthalmia (%)	50/58 (86.21)	NA
Xerostomia (%)	54/58 (93.10)	NA
ANA(+) (%)	50/58 (86.21)	NA
Anti-SSA(+) (%)	45/58 (77.59)	NA
Anti-SSB(+) (%)	19/58 (32.76)	NA
RF(+) (%)	31/58 (53.45)	NA
Increased ESR (%)	30/58 (51.72)	NA
Increased IgG (%)	28/58 (48.28)	NA
Increased -globulin (%)	38/58 (65.52)	NA
ESSDAI	3.86 ± 2.05	NA

ESSDAI: the EULAR-SS Disease Activity Index; ANA: antinuclear antibody; Anti-SSA: anti-Ro/SSA antibody; anti-SSB: anti-La/SSB antibody; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; IgG: immunoglobulin A; HCs: healthy controls; NA: not applicable. Numerical data presented as mean ± SD were analyzed using Student’s t-test or Pearson’s Chi-squared test. was taken as significant.